^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Merkel Cell Carcinoma
    Drug:Zynyz (retifanlimab-dlwr) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    03/22/2023
    Excerpt:
    ZYNYZ is a programmed death receptor-1 (PD-1)–blocking antibody indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    04/10/2023
    Excerpt:
    Merkel Cell Carcinoma...Other recommended regimen:...Retifanlimab-dlwr if patient is not amenable to surgery or RT.